Trial Profile
A Phase I/II Open Label Multi Center Study of Immune Checkpoint Therapy With Nivolumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 29 Mar 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Carboplatin; Paclitaxel
- Indications Carcinoma; Oesophageal cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 02 Mar 2022 Status changed from active, no longer recruiting to discontinued.
- 24 Mar 2021 Planned End Date changed from 31 Dec 2020 to 1 Jun 2021.
- 24 Mar 2021 Planned primary completion date changed from 31 Dec 2020 to 1 Jun 2021.